[ 4 ] Buckley MM, Goa KL, Price AH, et al. Probucol. a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia[J]. Drugs, 1989, 37(6): 761-800.
[ 8 ] Jeon H, Lee S, Kim TE, et al. Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers[J]. Int J Clin Pharmacol Ther, 2011, 49(11): 688-695.
[9]
[ 9 ] Kim KP, Kim BH, Lim KS, et al. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers[J]. Clin Ther, 2009, 31(10): 2098-2106.
[10]
Jiko M, Yano I, Wakasugi H, et al. Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats[J]. Pharm Res, 2002, 19(9): 1362-1367.
[11]
Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender[J]. Am Heart J, 1996, 131(6): 1184-1191.
[12]
Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study[J]. J Hepatol, 2003, 38(4): 414-418.
